LG

■ ‘LC542019’, new drug material with mechanism for improving desensitized insulin reaction
- Plans to evaluate safety and maximum tolerance dose for healthy adults and patients with type 2 diabetes
 
■ Procured 10 new drug materials in clinical development stages in 5 years since launching of the Life Sciences Company
 
■ Goal of developing new diabetes drug that improves insulin resistance while also having additional effects
- Effective improvement of blood-sugar and additional effects of weight loss verified through pre-clinical results
 
 
LG Chem will develop a new diabetes drug that improves desensitized insulin reactions.
 
LG Chem announced on the 19th that it received approval for clinical phase 1 studies (investigational new drug; IND) for ‘LC542019’, which is a new drug candidate material for treating type 2 diabetes that can improve insulin resistance from the US FDA.
 
With the approval for clinical stage 1 trials of ‘LC542019,’ the Life Sciences Company has now procured a total of 10 new drug candidate materials in clinical development stages including the gout medicine ‘Tigulixostat’ in just five years since the launching of the company.
 
LG Chem will conduct evaluations on the safety, drug fastness, pharmacokinetics (absorption, distribution, metabolism, and secretion process of drug) and pharmacodynamics (drug concentration and treatment effects) on 98 healthy adults and patients with type 2 diabetes in the US.
 
‘LC542019’ is a drug that improves insulin resistance by activating effects of ‘GPR120,’ which is an insulin sensitivity regulating protein.
 
Insulin moves glucose in the blood to inside the cell to help it be used as an energy source or for storing in the cell. When insulin resistance of the cell rises, even if insulin is secreted, movement of glucose between the blood and cells does not occur properly, thus turning into a state of high blood-sugar.
 
LG Chem plans to develop a distinguished diabetes drug that not only has powerful blood-sugar reduction effects by improving insulin resistance, but also having additional effects such as weight loss and helping with fatty liver. Pre-clinical results of ‘LC542019’ confirmed effective blood-sugar improvements, as well as additional effects like weight loss.
 
According to the market survey data (GlobalData), the global market for type 2 diabetes drugs is expected to grow continuously from 67 trillion KRW (56.5 billion USD) in 2021 to 109 trillion KRW (91.9 billion USD) by 2029. 
 
President of the Life Sciences Company Jeewong Son stated, “We will develop innovative new drugs distinguished from existing diabetes medicines based on our R&D expertise in diabetic diseases,” while adding, “We will maximize the growth potential of the Life Sciences Company by accelerating global clinical development in strategic disease groups and by continuously discovering clinical development projects.”